| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.009 | 0.9 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.0083 | 0.9 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |